ScholarLens Back to search
2014•Cochrane Database of Systematic ReviewsRequires access

Dimethyl fumarate for multiple sclerosis

Xu Zhu, Feng Zhang, Fangli Sun, KeFeng Gu, Shuai Dong, Dian He

Open publisher page 21 citations

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the absolute and comparative efficacy and safety of dimethyl fumarate as monotherapy or combination therapy versus placebo or other approved disease‐modifying drugs (IFN‐β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, alemtuzumab) for patients with MS.

About this research paper

What this paper is about

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the absolute and comparative efficacy and safety of dimethyl fumarate as monotherapy or combination therapy versus placebo or other approved disease‐modifying drugs (IFN‐β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, alemtuzumab) for patients with MS.

Why it matters

OpenAlex reports 21 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the absolute and comparative efficacy and safety of dimethyl fumarate as monotherapy or combination therapy versus placebo or other approved disease‐modifying drugs (IFN‐β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, alemtuzumab) for patients with MS.

Key concepts: Teriflunomide, Dimethyl fumarate, Glatiramer acetate, Fingolimod, Natalizumab, Multiple sclerosis, Medicine, Alemtuzumab

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Dimethyl fumarate for multiple sclerosis — Research Paper | ScholarLens